| Q28574928 | Angiotensin II reduces cardiac AdipoR1 expression through AT1 receptor/ROS/ERK1/2/c-Myc pathway |
| Q28566391 | Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor |
| Q35204828 | Cardiac NO signalling in the metabolic syndrome |
| Q92528676 | Cardiovascular Pleiotropic Effects of Natriuretic Peptides |
| Q47176304 | Carperitide induces coronary vasodilation and limits infarct size in canine ischemic hearts: role of NO. |
| Q36119104 | Chronic C-Type Natriuretic Peptide Infusion Attenuates Angiotensin II-Induced Myocardial Superoxide Production and Cardiac Remodeling |
| Q45812025 | Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes. |
| Q33769656 | Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II |
| Q24595411 | Effects of tempol and redox-cycling nitroxides in models of oxidative stress |
| Q35068336 | Endothelin-1 regulates cardiac L-type calcium channels via NAD(P)H oxidase-derived superoxide |
| Q54481875 | Enhanced phosphoinositide 3-kinase(p110α) activity prevents diabetes-induced cardiomyopathy and superoxide generation in a mouse model of diabetes. |
| Q46717606 | KMUP-1 Attenuates Endothelin-1-Induced Cardiomyocyte Hypertrophy through Activation of Heme Oxygenase-1 and Suppression of the Akt/GSK-3β, Calcineurin/NFATc4 and RhoA/ROCK Pathways. |
| Q37325178 | Low intrinsic exercise capacity in rats predisposes to age-dependent cardiac remodeling independent of macrovascular function. |
| Q37055845 | Molecular biology of the myocardial Na+/H+ exchanger |
| Q34636226 | Myocardial oxidative stress contributes to transgenic β₂-adrenoceptor activation-induced cardiomyopathy and heart failure. |
| Q28571259 | NPRA-mediated suppression of AngII-induced ROS production contribute to the antiproliferative effects of B-type natriuretic peptide in VSMC |
| Q37243593 | Natriuretic peptides in vascular physiology and pathology. |
| Q37157505 | Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. |
| Q37917873 | Nitric oxide synthase and cyclic GMP signaling in cardiac myocytes: from contractility to remodeling |
| Q34233761 | Nitroxyl (HNO) stimulates soluble guanylyl cyclase to suppress cardiomyocyte hypertrophy and superoxide generation |
| Q33631594 | Role of Nongenomic Signaling Pathways Activated by Aldosterone During Cardiac Reperfusion Injury |
| Q34951017 | Sex differences in the beneficial cardiac effects of chronic treatment with atrial natriuretic Peptide in spontaneously hypertensive rats |
| Q46322063 | Suppression of atrial natriuretic peptide/natriuretic peptide receptor-A-mediated signaling upregulates angiotensin-II-induced collagen synthesis in adult cardiac fibroblasts |
| Q36365175 | Systems pharmacology-based approach for dissecting the active ingredients and potential targets of the Chinese herbal Bufei Jianpi formula for the treatment of COPD. |
| Q80300386 | The antioxidant tempol inhibits cardiac hypertrophy in the insulin-resistant GLUT4-deficient mouse in vivo |
| Q93551245 | The novel NO redox sibling, nitroxyl (HNO), prevents cardiomyocyte hypertrophy and superoxide generation via cGMP |
| Q36380981 | The soluble guanylyl cyclase activator bay 58-2667 selectively limits cardiomyocyte hypertrophy |